# Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

> **NCT06539091** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Efficacy
- Safety
- Bone Mineral Density
- Tolerability

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Apatinib Mesylate

## Key facts

- **NCT ID:** NCT06539091
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06539091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06539091, "Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06539091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*